Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      ShangPharma Announces Second Quarter 2012 Results


      News provided by

      ShangPharma Corporation

      Aug 20, 2012, 06:00 ET

      Share this article

      Share this article


      SHANGHAI, Aug. 20, 2012 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its unaudited financial results for the second quarter ended June 30, 2012.

      Second Quarter 2012 Highlights

      • Net revenues increased by 15.7% year-over-year to $31.8 million.
      • Net revenues from the Company's top-10 customers increased by 21.3% year-over-year to $20.6 million, representing approximately 64.8% of total net revenues.
      • Net revenues from full-time-equivalent ("FTE")-based services increased by 21.0% year-over-year to $23.9 million.
      • GAAP gross margin was 27.8%, compared with 33.3% in the second quarter of 2011. Non-GAAP gross margin was 29.0%, compared with 34.7% in the second quarter of 2011.
      • GAAP operating margin was 2.4%, compared with 10.3% in the second quarter of 2011. Non-GAAP operating margin was 7.6% compared with 15.2% in the second quarter of 2011.

      Management Comment

      "I am pleased to report that during a challenging second quarter, ShangPharma made excellent progress on several key strategic goals, including increasing revenue from biologics and shifting more of our work to FTE-based services," said Michael Xin Hui, founder and Chief Executive Officer of ShangPharma. "It is a testament to the strength of our offering that global leading pharmaceutical and biotech companies continued to expand their relationships with us."

      Mr. Hui continued, "Our previously discussed investments helped us to win additional business, but also placed pressure on our margins this quarter. The increased competition that we saw in more mature service offerings in the second quarter strengthened our confidence in our long-term strategy to invest in capabilities, facilities and staff, allowing us to move up the research value chain. Our continuous investment in key areas such as integrated drug discovery, biologics, biology, process development and research manufacturing, and translational and clinical science, will be critical for strengthening our offering at the higher end of the research value chain. We believe this positions us well for long-term growth."

      William Dai, Chief Financial Officer, added, "Despite industry headwinds, we succeeded in increasing the percentage of revenues generated by FTE-based services, which have better visibility, as well as expanding our integrated drug discovery service offering to many of our larger customers. While margins were impacted by annual pay raises and benefit increases effective from April, we believe that these costs will remain relatively stable over the next several quarters. We have already begun to take a series of measures to reduce costs through improving operational efficiency."

      To help management and investors gain a better understanding of ShangPharma's operating performance, the Company presents certain non-GAAP measures, each of which excludes expenses relating to or the effect of share-based compensation. See "About Non-GAAP Financial Measures" and "Reconciliation of Unaudited GAAP to Non-GAAP Financial Data" below for more information about the non-GAAP financial measures included in this press release.

      Beginning in the first quarter 2012, in accordance with Accounting Standards Update 2011-05, the Company is presenting other comprehensive income and its components in the unaudited condensed consolidated statement of comprehensive income.   Other comprehensive income mainly consists of currency translation adjustments relating to translating some of our subsidiaries' financial statements from their functional currency to our reporting currency, which is in the United States dollar.   The functional currency of our main subsidiaries in China is the RMB.

      Second Quarter 2012 Results

      Net revenues were $31.8 million, an increase of 15.7% from $27.5 million in the second quarter of 2011. Higher volumes from the Company's top customers and greater cross-selling of services were major drivers of this growth. This increase was partially offset by the completion of some FTE-based services projects and a decrease in non-FTE projects. Revenues this quarter were partially impacted by a change in estimates of the expected performance of certain integrated services projects. 

      Net revenues from the Company's top-10 customers increased by 21.3% compared with the same period last year, representing approximately 64.8% of total net revenues, compared with 61.8% in the same quarter last year. The growth was a result of global leading pharmaceutical and biotech companies expanding their scope of work and business volumes with the Company. This increase was driven by our investments in expanding our facilities and adding new capabilities during 2011. The growth demonstrates steady progress in our efforts to become a preferred business partner of global leading pharmaceutical and biotech companies.

      Net revenues from FTE-based services were $23.9 million, an increase of 21.0% from $19.7 million in the second quarter of 2011. The growth was largely a result of global leading pharmaceutical and biotech companies expanding their scope of work and business volumes with the Company. Additionally, the growth was in part due to an increase in volume as a result of our strategic shift towards FTE-based services, which have greater visibility.

      Net revenues from fee-for-service-based services were $7.9 million, an increase of 2.2% from $7.8 million in the second quarter of 2011. Revenues this quarter were partially impacted by a change in estimates of the expected performance of certain integrated services projects.

      Gross profit was $8.9 million, a decrease of 3.2% from $9.1 million in the second quarter of 2011. The decrease was primarily due to the costs associated with our new facilities, some of which have not yet reached full utilization. Specifically, the manufacturing business operating at our Fengxian facility will take several additional quarters to reach good utilization. Other factors impacting our quarterly performance include higher labor costs as a percentage of total net revenues due to increased headcount to support our near future business growth and annual pay raises and benefit increases effective from April, 2012. These factors were partially offset by the increase in net revenues and cost savings resulting from the value-added-tax ("VAT") reform in Shanghai effective January 1, 2012.

      Non-GAAP gross profit was $9.2 million, a decrease of 3.2% from $9.5 million in the second quarter of 2011. This was due to the reasons mentioned in the above discussion of GAAP gross profit.

      Gross margin was 27.8%, compared with 33.3% in the second quarter of 2011. This was primarily due to the reasons mentioned in the above discussion of GAAP gross profit. These factors were partially offset by the cost savings from the aforementioned VAT reform. The investments and upgrades to our facilities made during 2011, including the build-up of the Fengxian facility and the Charles River asset acquisition, are critical in positioning us for future growth and expanding further into higher-value added services.

      Non-GAAP gross margin was 29.0%, compared with 34.7% in the second quarter of 2011. This decrease was due to the reasons mentioned in the above discussion of GAAP gross margin.

      Operating expenses (selling and marketing, general and administrative) were $8.1 million, an increase of 28.1% from $6.3 million in the second quarter of 2011. This was primarily due to higher labor costs resulting from the addition of senior leaders across our various service offerings during the first half of 2012, annual pay raises and benefit increases effective from April 2012, higher listed company-related professional fees, higher share-based compensation expenses and higher selling and marketing expenses as a result of our enhanced business development efforts during the quarter. The enhancement of our senior scientific team is critical in positioning the Company for expansion into new capabilities and maintaining the Company's competitiveness in the market. The enhanced marketing efforts included a focus on meeting with global customers, and help communicate the value of our expanding services offering. We anticipate that these efforts will result in increased revenue in the future.

      Non-GAAP operating expenses were $6.8 million, an increase of 27.0% from $5.4 million in the second quarter of 2011. This was primarily due to the reasons mentioned in the above discussion of operating expenses, excluding the impact of share-based compensation expenses.

      Profit from operations was $0.8 million, a decrease of 73.1% from $2.8 million in the second quarter of 2011, primarily due to facility expansion costs, higher labor costs resulting from annual pay raises and benefit increases effective from April 2012 and an increase in the number of our scientific research staff members, including senior scientists, during the first half of 2012,  higher listed company-related professional fees, higher share-based compensation expenses, and higher selling and marketing expenses. These factors were partially offset by an increase in net revenues and cost savings from the aforementioned VAT reform. 

      Non-GAAP profit from operations was $2.4 million, a decrease of 42.1% from $4.2 million in the second quarter of 2011. This was due to the reasons mentioned in the above discussion of GAAP profit from operations, excluding the impact of share-based compensation expenses.

      Operating margin was 2.4%, compared with 10.3% in the second quarter of 2011.  This decrease was primarily due to facility expansion costs, higher labor costs as a percentage of total net revenues, higher listed company-related professional fees, higher share-based compensation expenses, and higher selling and marketing expenses. These were partially offset by cost savings resulting from the aforementioned VAT reform.

      Non-GAAP operating margin was 7.6%, compared with 15.2% in the second quarter of 2011. This decrease was primarily due to the reasons mentioned in the above discussion of GAAP operating margin, excluding the impact of share-based compensation expenses.

      Net income decreased by 87.8% year over year to $0.4 million, primarily due to lower profit from operations and a significant unrealized foreign exchange forward contract mark-to-market loss amounting to $1.7 million, due to the RMB depreciation against the U.S. dollar during the quarter leading to continuing depreciation anticipation and lower interest income. These items were partially offset by a tax benefit recognized during the quarter as a result of the tax preference for the super deduction of research and development expenses in calculating one of our subsidiaries' 2011 income tax expenses, which was formally approved by the local tax bureau in the second quarter of 2012. Such tax preferences were not considered in our 2011 income tax expenses as we had not yet received formal approval from the local tax bureau.

      Non-GAAP net income was $2.1 million, a decrease of 56.0% from $4.7 million in the second quarter of 2011. This was primarily due to the reasons mentioned in the above discussion of GAAP net income. 

      Diluted earnings per ADS were $0.02, which compares with $0.18 in the second quarter of 2011.

      Non-GAAP diluted earnings per ADS were $0.11, which compares with $0.25 in the second quarter of 2011.

      Financial Position 

      As of June 30, 2012, the Company had cash and cash equivalents of $34.7 million and no debt outstanding.  During the quarter, capital expenditures totaled $3.9 million, primarily from purchase of equipment and investment in leasehold improvements of our various facilities.

      Full Year 2012 Guidance

      The Company revises its previously announced guidance for non-GAAP gross margin for the full year 2012, and reconfirms its guidance for net revenues and capital expenditures for the full year 2012. The Company expects:

      • Net revenues to be approximately $131.7 – $136.2 million, which represents growth of approximately 18.0% – 22.0% compared with the full year of 2011. 
      • Non-GAAP gross margin to be approximately 30.0% – 31.5%, compared to the previously announced range of 31.5% – 33.5%.
      • Capital expenditures to be approximately $20.0 - $24.0 million.

      This reflects the Company's current view and is subject to change.

      Conference Call

      ShangPharma will host a conference call and live webcast at 8:00AM U.S. Eastern Time on August 20, 2012 (8:00PM Beijing Time on August 20, 2012). 

      The dial-in details for the live conference call are as follows:

      - International:

      +1-718-354-1231



      - United States:

      +1-866-519-4004  

      - United Kingdom:

      +080-8234-6646

      - Hong Kong:

      +852-2475-0994



       Passcode:  SHP


      A live and archived webcast of the conference call will be available on the Investor Relations section of ShangPharma's website at www.shangpharma.com.

      A telephone replay of the call will be available for seven days from August 20, 2012, 11:00AM U.S. Eastern Time to August 27, 2012, 11:59PM U.S. Eastern Time.

      The dial-in details for the replay are as follows:

      - International:

      +61-2-8235-5000

      - Passcode:

      17558472

      ABOUT SHANGPHARMA CORPORATION

      ShangPharma Corporation (NYSE: SHP) is a leading China-based contract research organization providing high quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com.

      Safe Harbor: Forward-Looking Statements

      This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "likely to" or other similar expressions. The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. Among other things, the section titled "Full Year 2012 Guidance" and quotations from management in this press release, as well as the Company's strategic and operational plans, contain forward-looking statements. The Company may also make written or oral forward-looking statements in its reports filed or furnished with the U.S. Securities and Exchange Commission, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements and are subject to change, and such change may be material and may have a material adverse effect on the Company's financial condition and results of operations for one or more periods. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained, either expressly or impliedly, in any of the forward-looking statements in this press release. The Company expects to face potential risks and uncertainties related to its ability to, among other things, attract, train, motivate and retain skilled scientists; diversify its customer base and adapt to potential loss of sales to, or significant reduction in orders from, any of its major customers; adapt its business to industry trends, such as fluctuations in the R&D budgets of pharmaceutical and biotechnology industry participants; protect the intellectual property rights of its customers; comply with applicable regulations and industry standards; compete effectively in its industry, which may subject it to increasing pricing pressure and reduce the demand for its services; expand and market its services and manage its growth; and develop and maintain effective internal control over financial reporting; as well as other risks outlined in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of this press release, and the Company does not undertake any obligation to update any such information, except as required under applicable law.

      About Non-GAAP Financial Measures

      To supplement the Company's consolidated financial results presented in accordance with United States Generally Accepted Accounting Principles ("GAAP"), the Company uses the following non-GAAP financial measures: (1) gross profit, (2) gross margin, (3) profit from operations, (4) operating expenses, (5) operating margin, (6) net income, and (7) diluted earnings per ADS, each of which excludes expenses relating to or the effect of share-based compensation. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. For more information on these non-GAAP financial measures, please see the table captioned "Reconciliation of Unaudited GAAP and non-GAAP Financial Data" set forth at the end of this press release.

      The Company believes that these non-GAAP financial measures provide meaningful supplemental information regarding its operating performance by excluding expenses relating to or the effect of share-based compensation that may not be indicative of its operating performance. The Company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing its operating performance and when planning and forecasting future periods. These non-GAAP financial measures also facilitate management's internal comparisons to the Company's historical performance. The Company computes its non-GAAP financial measures using the same consistent method from quarter to quarter. The Company believes these non-GAAP financial measures are useful to investors in allowing for greater transparency with respect to supplemental information used by management in its financial and operational decision making. A limitation of using non-GAAP financial measures excluding expenses relating to or the effect of share-based compensation is that these expenses and effects have been and will continue to be significant recurring expenses in the Company's business for the foreseeable future. Management compensates for these limitations by providing specific information regarding the GAAP amount excluded from each non-GAAP measure. The accompanying tables have more details on the reconciliation between non-GAAP financial measures and their most comparable GAAP financial measures.

      For further information, please contact:

      ShangPharma Corporation
      William Dai
      Chief Financial Officer
      E-mail: [email protected]

      Brunswick Group   
      Josh Gartner
      E-mail:[email protected]
      Phone: 86-10-5960-8600

      SHANGPHARMA CORPORATION
      UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEET
      (in thousands of U.S. dollars, except for ordinary share data)


      December 31, 

      June 30, 


      2011

      2012




      ASSETS



      Current assets:



        Cash and cash equivalents

      37,778

      34,738

        Restricted cash

      2,562

      1,156

        Accounts receivable, net

      23,974

      27,203

        Amounts due from related parties

      503

      765

        Inventories

      2,842

      2,752

        Prepayments and others

      4,425

      2,683

        Deferred tax assets

      264

      925

      Total current assets

      72,348

      70,222

      Non-current assets:



        Derivative assets

      7

      -

        Property, plant, equipment and software, net

      86,521

      88,583

        Land use right, net

      6,634

      6,539

        Other long-term assets

      559

      633

        Amounts due from related parties

      225

      224

        Deferred tax assets

      609

      620

      Total non-current assets

      94,555

      96,599

      Total assets

      166,903

      166,821




      LIABILITIES



      Current liabilities:



        Accounts payable

      16,307

      15,331

        Amounts due to related parties

      123

      489

        Salary and welfare payable

      3,864

      2,325

        Income tax payable

      3,241

      1,437

        Advance from customers

      1,596

      738

        Other payables and accruals

      5,613

      4,998

      Total current liabilities

      30,744

      25,318

      Non-current liabilities:



        Advanced subsidies

      3,121

      4,179

      Total non-current liabilities

      3,121

      4,179

      Total liabilities

      33,865

      29,497

      Commitments and contingencies






      EQUITY



      Ordinary shares (US$0.001 par value; 500,000,000 shares
      authorized; 336,109,400 and 337,973,959 shares issued
      and outstanding as of December 31, 2011 and June 30, 2012,
      respectively)

      336

      336

      Additional paid in capital

      84,924

      87,948

      Statutory reserves

      8,552

      8,552

      Retained earnings

      33,013

      35,155

      Accumulated other comprehensive income

      7,305

      7,017

      Less: Treasury stock, at cost; 2,237,148 and 3,681,666 shares as of
      December 31, 2011 and June 30, 2012, respectively

      (1,092)

      (1,684)

      Total equity

      133,038

      137,324

      Total liabilities and equity

      166,903

      166,821

        SHANGPHARMA CORPORATION
      UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
      (in thousands of U.S. dollars, except for ADS1 data and per ADS data)


      Three months ended

      Six months ended


      June 30,

      June 30,


      2011

      2012

      % Change

      2011

      2012

      % Change








      Net revenue

      27,508

      31,826

      15.7%

      52,282

      62,580

      19.7%

      Cost of revenue

      (18,359)

      (22,967)

      25.1%

      (35,134)

      (44,425)

      26.4%

      Gross profit

      9,149

      8,859

      -3.2%

      17,148

      18,155

      5.9%








      Operating expenses







           Selling and marketing

      (588)

      (900)

      53.1%

      (1,061)

      (1,589)

      49.8%

           General and administrative

      (5,732)

      (7,350)

      28.2%

      (10,781)

      (14,543)

      34.9%

           Other operating income2

      -

      221


      -

      585


           Other operating expenses2

      -

      (70)


      -

      (235)


      Total operating expenses

      (6,320)

      (8,099)

      28.1%

      (11,842)

      (15,782)

      33.3%








      Profit from operations

      2,829

      760

      -73.1%

      5,306

      2,373

      -55.3%








      Other income (expenses), net2:

      1,350

      (1,200)

      -188.9%

      2,403

      (664)

      -127.6%

      Income from operations before income taxes

      4,179

      (440)

      -110.5%

      7,709

      1,709

      -77.8%








      Income taxes

      (827)

      849

      -202.7%

      (1,347)

      432

      -132.1%

      Net income

      3,352

      409

      -87.8%

      6,362

      2,141

      -66.3%








      Net income per ADS 







           Basic

      0.18

      0.02

      -88.9%

      0.34

      0.12

      -64.7%

           Diluted

      0.18

      0.02

      -88.9%

      0.34

      0.12

      -64.7%








      Weighted average ADS outstanding







           Basic

      18,653,713

      18,538,232


      18,649,105

      18,531,864


           Diluted

      18,820,194

      18,552,031


      18,883,968

      18,542,477









      Net income

      3,352

      409

      -87.8%

      6,362

      2,141

      -66.3%

      Other comprehensive income:







      Currency translation adjustments, net

      876

      (389)

      -144.4%

      1,615

      (288)

      -117.8%

      Comprehensive income

      4,228

      20

      -99.5%

      7,977

      1,853

      -76.8%

      1 Assumes all outstanding ordinary shares are represented by ADSs. Each ADS represents 18 ordinary shares.
      2 Certain government subsidies and the related costs were reclassified to other operating income/expense since the third quarter of 2011 as a result of an accounting policy change to better reflect the nature of such transactions. The change is accounting policy was not retroactively applied due to immateriality.

      SHANGPHARMA CORPORATION

      RECONCILIATION OF UNAUDITED GAAP TO NON-GAAP FINANCIAL DATA

      (in thousands of U.S. dollars, except for ADS2 data and per ADS data)


                          Three months ended                    

                            Six months ended                        


      June 30,

      June 30,


      2011

      2012

      %

      2011

      2012

      %

      GAAP gross profit

      9,149

      8,859

      -3.2%

      17,148

      18,155

      5.9%

      GAAP gross margin

      33.3%

      27.8%


      32.8%

      29.0%


      Adjustments:







          Share-based compensation

      390

      371

      -4.9%

      988

      645

      -34.7%

      Non-GAAP gross profit

      9,539

      9,230

      -3.2%

      18,136

      18,800

      3.7%

      Non-GAAP gross margin

      34.7%

      29.0%


      34.7%

      30.0%









      GAAP operating expenses

      (6,320)

      (8,099)

      28.1%

      (11,842)

      (15,782)

      33.3%

      Adjustments:







          Share-based compensation

      959

      1,289

      34.4%

      1,730

      2,379

      37.5%

      Non-GAAP operating expenses

      (5,361)

      (6,810)

      27.0%

      (10,112)

      (13,403)

      32.5%








      GAAP profit from operations

      2,829

      760

      -73.1%

      5,306

      2,373

      -55.3%

      GAAP operating margin

      10.3%

      2.4%


      10.1%

      3.8%


      Adjustments:







          Share-based compensation

      1,349

      1,660

      23.1%

      2,718

      3,024

      11.3%

      Non-GAAP profit from operations

      4,178

      2,420

      -42.1%

      8,024

      5,397

      -32.7%

      Non-GAAP operating margin

      15.2%

      7.6%


      15.3%

      8.6%









      GAAP net income

      3,352

      409

      -87.8%

      6,362

      2,141

      -66.3%

      GAAP net margin

      12.2%

      1.3%


      12.2%

      3.4%


      Adjustments:







          Share-based compensation

      1,349

      1,660

      23.1%

      2,718

      3,024

      11.3%

      Non-GAAP net income

      4,701

      2,069

      -56.0%

      9,080

      5,165

      -43.1%

      Non-GAAP net margin 

      17.1%

      6.5%


      17.4%

      8.3%









      GAAP net income per ADS, diluted:                

      0.18

      0.02

      -88.9%

      0.34

      0.12

      -64.7%

      Adjustments:







          Share-based compensation

      0.07

      0.09


      0.14

      0.16


      Non-GAAP net income per ADS, diluted:

      0.25

      0.11

      -56.0%

      0.48

      0.28

      -41.7%








      Weighted average ADS outstanding - basic (Non-GAAP)

      18,653,713

      18,538,232


      18,649,105

      18,531,864


      Weighted average ADS outstanding - diluted (Non-GAAP)

      18,820,194

      18,552,031


      18,883,968

      18,542,477


      2 Assumes all outstanding ordinary shares are represented by ADSs. Each ADS represents 18 ordinary shares.

      SOURCE ShangPharma Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.